JP2016523919A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016523919A5 JP2016523919A5 JP2016524268A JP2016524268A JP2016523919A5 JP 2016523919 A5 JP2016523919 A5 JP 2016523919A5 JP 2016524268 A JP2016524268 A JP 2016524268A JP 2016524268 A JP2016524268 A JP 2016524268A JP 2016523919 A5 JP2016523919 A5 JP 2016523919A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acids
- seq
- chimeric molecule
- vwf
- item
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001413 amino acids Chemical class 0.000 claims description 200
- 108010047303 von Willebrand Factor Proteins 0.000 claims description 93
- 102100036537 von Willebrand factor Human genes 0.000 claims description 93
- 108010054218 Factor VIII Proteins 0.000 claims description 69
- 102000001690 Factor VIII Human genes 0.000 claims description 69
- 229960001134 von willebrand factor Drugs 0.000 claims description 59
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 43
- 239000002157 polynucleotide Substances 0.000 claims description 42
- 102000040430 polynucleotide Human genes 0.000 claims description 42
- 108091033319 polynucleotide Proteins 0.000 claims description 42
- 229960000301 factor viii Drugs 0.000 claims description 41
- 229920001184 polypeptide Polymers 0.000 claims description 39
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 39
- 239000013598 vector Substances 0.000 claims description 26
- 230000000740 bleeding effect Effects 0.000 claims description 24
- 108090000190 Thrombin Proteins 0.000 claims description 19
- 229960004072 thrombin Drugs 0.000 claims description 19
- 239000012634 fragment Substances 0.000 claims description 14
- 101001098529 Homo sapiens Proteinase-activated receptor 1 Proteins 0.000 claims description 11
- 101000713169 Homo sapiens Solute carrier family 52, riboflavin transporter, member 2 Proteins 0.000 claims description 11
- 102100036862 Solute carrier family 52, riboflavin transporter, member 2 Human genes 0.000 claims description 11
- 230000003993 interaction Effects 0.000 claims description 11
- 238000003776 cleavage reaction Methods 0.000 claims description 9
- 230000007017 scission Effects 0.000 claims description 9
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 8
- 102000009786 Immunoglobulin Constant Regions Human genes 0.000 claims description 8
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 7
- -1 aliphatic amino acid Chemical group 0.000 claims description 6
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 102000002110 C2 domains Human genes 0.000 claims description 2
- 108050009459 C2 domains Proteins 0.000 claims description 2
- 241001024304 Mino Species 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- 230000000295 complement effect Effects 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- YMAWOPBAYDPSLA-UHFFFAOYSA-N glycylglycine Chemical compound [NH3+]CC(=O)NCC([O-])=O YMAWOPBAYDPSLA-UHFFFAOYSA-N 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 102000004169 proteins and genes Human genes 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 5
- 235000001014 amino acid Nutrition 0.000 description 143
- 229940024606 amino acid Drugs 0.000 description 142
- 208000032843 Hemorrhage Diseases 0.000 description 20
- 208000034158 bleeding Diseases 0.000 description 20
- 238000000034 method Methods 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 13
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 8
- 102000009027 Albumins Human genes 0.000 description 5
- 108010088751 Albumins Proteins 0.000 description 5
- 101800001415 Bri23 peptide Proteins 0.000 description 5
- 101800000655 C-terminal peptide Proteins 0.000 description 5
- 102400000107 C-terminal peptide Human genes 0.000 description 5
- 229920001612 Hydroxyethyl starch Polymers 0.000 description 4
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 description 4
- 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 229940050526 hydroxyethylstarch Drugs 0.000 description 4
- 239000002773 nucleotide Substances 0.000 description 4
- 125000003729 nucleotide group Chemical group 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 230000000694 effects Effects 0.000 description 3
- 101100380342 Catharanthus roseus ASO gene Proteins 0.000 description 2
- 108010062540 Chorionic Gonadotropin Proteins 0.000 description 2
- 102000011022 Chorionic Gonadotropin Human genes 0.000 description 2
- 229940084986 human chorionic gonadotropin Drugs 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 238000013169 thromboelastometry Methods 0.000 description 2
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 206010019196 Head injury Diseases 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 108010015340 Low Density Lipoprotein Receptor-Related Protein-1 Proteins 0.000 description 1
- 206010028309 Muscle haemorrhage Diseases 0.000 description 1
- 102100021923 Prolow-density lipoprotein receptor-related protein 1 Human genes 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 208000015294 blood coagulation disease Diseases 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 208000030304 gastrointestinal bleeding Diseases 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 210000000574 retroperitoneal space Anatomy 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361840872P | 2013-06-28 | 2013-06-28 | |
| US61/840,872 | 2013-06-28 | ||
| PCT/US2014/044731 WO2014210558A1 (en) | 2013-06-28 | 2014-06-27 | Thrombin cleavable linker with xten and its uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018195860A Division JP2019010124A (ja) | 2013-06-28 | 2018-10-17 | Ｘｔｅｎを有するトロンビン切断可能リンカー及びその使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016523919A JP2016523919A (ja) | 2016-08-12 |
| JP2016523919A5 true JP2016523919A5 (enExample) | 2017-08-10 |
Family
ID=52142742
Family Applications (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016524268A Pending JP2016523919A (ja) | 2013-06-28 | 2014-06-27 | Ｘｔｅｎを有するトロンビン切断可能リンカー及びその使用 |
| JP2018195860A Pending JP2019010124A (ja) | 2013-06-28 | 2018-10-17 | Ｘｔｅｎを有するトロンビン切断可能リンカー及びその使用 |
| JP2021018123A Active JP7005800B2 (ja) | 2013-06-28 | 2021-02-08 | Ｘｔｅｎを有するトロンビン切断可能リンカー及びその使用 |
| JP2021163956A Active JP7297837B2 (ja) | 2013-06-28 | 2021-10-05 | Ｘｔｅｎを有するトロンビン切断可能リンカー及びその使用 |
| JP2023097660A Active JP7623426B2 (ja) | 2013-06-28 | 2023-06-14 | Ｘｔｅｎを有するトロンビン切断可能リンカー及びその使用 |
| JP2025005420A Pending JP2025061316A (ja) | 2013-06-28 | 2025-01-15 | Ｘｔｅｎを有するトロンビン切断可能リンカー及びその使用 |
Family Applications After (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018195860A Pending JP2019010124A (ja) | 2013-06-28 | 2018-10-17 | Ｘｔｅｎを有するトロンビン切断可能リンカー及びその使用 |
| JP2021018123A Active JP7005800B2 (ja) | 2013-06-28 | 2021-02-08 | Ｘｔｅｎを有するトロンビン切断可能リンカー及びその使用 |
| JP2021163956A Active JP7297837B2 (ja) | 2013-06-28 | 2021-10-05 | Ｘｔｅｎを有するトロンビン切断可能リンカー及びその使用 |
| JP2023097660A Active JP7623426B2 (ja) | 2013-06-28 | 2023-06-14 | Ｘｔｅｎを有するトロンビン切断可能リンカー及びその使用 |
| JP2025005420A Pending JP2025061316A (ja) | 2013-06-28 | 2025-01-15 | Ｘｔｅｎを有するトロンビン切断可能リンカー及びその使用 |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US20160251408A1 (enExample) |
| EP (2) | EP3013358A4 (enExample) |
| JP (6) | JP2016523919A (enExample) |
| KR (4) | KR102865153B1 (enExample) |
| CN (3) | CN105392495A (enExample) |
| AU (3) | AU2014302100B2 (enExample) |
| CA (1) | CA2913078A1 (enExample) |
| CL (1) | CL2015003710A1 (enExample) |
| EA (1) | EA201592022A1 (enExample) |
| HK (1) | HK1223302A1 (enExample) |
| IL (3) | IL297611B2 (enExample) |
| MX (1) | MX2015016567A (enExample) |
| NZ (1) | NZ713904A (enExample) |
| PH (1) | PH12015502614A1 (enExample) |
| SG (3) | SG11201509313PA (enExample) |
| TW (3) | TWI770467B (enExample) |
| WO (1) | WO2014210558A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2470670A4 (en) | 2009-08-24 | 2013-07-10 | Amunix Operating Inc | COAGULATION FACTOR VII COMPOSITIONS AND METHODS OF PREPARATION AND USE THEREOF |
| EP2804623B1 (en) | 2012-01-12 | 2019-08-07 | Bioverativ Therapeutics Inc. | Chimeric factor viii polypeptides and uses thereof |
| ES2771208T3 (es) | 2012-02-15 | 2020-07-06 | Bioverativ Therapeutics Inc | Composiciones de factor VIII y métodos de preparación y uso de las mismas |
| BR112014019901A8 (pt) | 2012-02-15 | 2018-01-02 | Biogen Idec Inc | Proteínas de fator viii recombinante |
| EP2870250B2 (en) | 2012-07-06 | 2022-06-29 | Bioverativ Therapeutics Inc. | Cell line expressing single chain factor viii polypeptides and uses thereof |
| US10138291B2 (en) * | 2012-07-11 | 2018-11-27 | Bioverativ Therapeutics Inc. | Factor VIII complex with XTEN and von Willebrand Factor protein, and uses thereof |
| EP3033097B1 (en) | 2013-08-14 | 2021-03-10 | Bioverativ Therapeutics Inc. | Factor viii-xten fusions and uses thereof |
| PT3091997T (pt) * | 2014-01-10 | 2022-09-29 | Bioverativ Therapeutics Inc | Proteínas quiméricas de fator viii e utilizações destas |
| SG11201706657PA (en) * | 2015-03-06 | 2017-09-28 | Csl Behring Recombinant Facility Ag | Compounds for improving the half-life of von willebrand factor |
| BR112018002150A2 (pt) | 2015-08-03 | 2018-09-18 | Bioverativ Therapeutics Inc | proteínas de fusão do fator ix e métodos de fabricação e uso das mesmas |
| JP6877469B2 (ja) * | 2016-06-24 | 2021-05-26 | モガム・インスティテュート・フォー・バイオメディカル・リサーチＭｏｇａｍ Ｉｎｓｔｉｔｕｔｅ Ｆｏｒ Ｂｉｏｍｅｄｉｃａｌ Ｒｅｓｅａｒｃｈ | Ｆｖｉｉｉおよびｖｗｆ因子を含むキメラタンパク質、ならびにそれらの使用 |
| AU2017358861B2 (en) * | 2016-11-11 | 2022-02-17 | CSL Behring Lengnau AG | Truncated von Willebrand Factor polypeptides for treating hemophilia |
| US12161696B2 (en) | 2016-12-02 | 2024-12-10 | Bioverativ Therapeutics Inc. | Methods of treating hemophilic arthropathy using chimeric clotting factors |
| DK3793588T3 (da) | 2018-05-18 | 2025-06-16 | Bioverativ Therapeutics Inc | Fremgangsmåder til behandling af hæmofili a |
| KR20210052389A (ko) | 2018-08-27 | 2021-05-10 | 리제너론 파마슈티칼스 인코포레이티드 | 다운스트림 정제에서의 라만 분광법의 사용 |
Family Cites Families (89)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US4215051A (en) | 1979-08-29 | 1980-07-29 | Standard Oil Company (Indiana) | Formation, purification and recovery of phthalic anhydride |
| US4713339A (en) | 1983-01-19 | 1987-12-15 | Genentech, Inc. | Polycistronic expression vector construction |
| US4757006A (en) | 1983-10-28 | 1988-07-12 | Genetics Institute, Inc. | Human factor VIII:C gene and recombinant methods for production |
| US4965199A (en) | 1984-04-20 | 1990-10-23 | Genentech, Inc. | Preparation of functional human factor VIII in mammalian cells using methotrexate based selection |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4965188A (en) | 1986-08-22 | 1990-10-23 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme |
| US5981216A (en) | 1985-04-01 | 1999-11-09 | Alusuisse Holdings A.G. | Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same |
| DE3683980D1 (de) | 1985-04-12 | 1992-04-02 | Genetics Inst | Neue prokoagulierungsproteine. |
| KR910006424B1 (ko) | 1985-08-21 | 1991-08-24 | 인코텍스 비.브이 | 편성브리프(brief) 제조방법 |
| WO1987004187A1 (en) | 1986-01-03 | 1987-07-16 | Genetics Institute, Inc. | METHOD FOR PRODUCING FACTOR VIII:c-TYPE PROTEINS |
| US5595886A (en) | 1986-01-27 | 1997-01-21 | Chiron Corporation | Protein complexes having Factor VIII:C activity and production thereof |
| US4800159A (en) | 1986-02-07 | 1989-01-24 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences |
| US5610278A (en) | 1986-06-24 | 1997-03-11 | Novo Nordisk A/S | Process for producing a coagulation active complex of factor VIII fragments |
| US4912040A (en) | 1986-11-14 | 1990-03-27 | Genetics Institute, Inc. | Eucaryotic expression system |
| CA1331157C (en) | 1987-04-06 | 1994-08-02 | Randal J. Kaufman | Method for producing factor viii:c-type proteins |
| US6060447A (en) | 1987-05-19 | 2000-05-09 | Chiron Corporation | Protein complexes having Factor VIII:C activity and production thereof |
| IL86693A (en) | 1987-06-12 | 1994-06-24 | Stichting Centraal Lab | Proteins with factor VIII activity, process for their preparation using genetically engineered cells and pharmaceutical compositions containing them |
| US6346513B1 (en) | 1987-06-12 | 2002-02-12 | Baxter Trading Gmbh | Proteins with factor VIII activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them |
| DE3720246A1 (de) | 1987-06-19 | 1988-12-29 | Behringwerke Ag | Faktor viii:c-aehnliches molekuel mit koagulationsaktivitaet |
| FR2619314B1 (fr) | 1987-08-11 | 1990-06-15 | Transgene Sa | Analogue du facteur viii, procede de preparation et composition pharmaceutique le contenant |
| US4994371A (en) | 1987-08-28 | 1991-02-19 | Davie Earl W | DNA preparation of Christmas factor and use of DNA sequences |
| US5004803A (en) | 1988-11-14 | 1991-04-02 | Genetics Institute, Inc. | Production of procoagulant proteins |
| SE465222C5 (sv) | 1989-12-15 | 1998-02-10 | Pharmacia & Upjohn Ab | Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning |
| US5846951A (en) | 1991-06-06 | 1998-12-08 | The School Of Pharmacy, University Of London | Pharmaceutical compositions |
| US5364771A (en) | 1992-04-07 | 1994-11-15 | Emory University | Hybrid human/porcine factor VIII |
| US5859204A (en) | 1992-04-07 | 1999-01-12 | Emory University | Modified factor VIII |
| US6376463B1 (en) | 1992-04-07 | 2002-04-23 | Emory University | Modified factor VIII |
| US6037452A (en) * | 1992-04-10 | 2000-03-14 | Alpha Therapeutic Corporation | Poly(alkylene oxide)-Factor VIII or Factor IX conjugate |
| US5563045A (en) | 1992-11-13 | 1996-10-08 | Genetics Institute, Inc. | Chimeric procoagulant proteins |
| SE504074C2 (sv) | 1993-07-05 | 1996-11-04 | Pharmacia Ab | Proteinberedning för subkutan, intramuskulär eller intradermal administrering |
| US5643575A (en) | 1993-10-27 | 1997-07-01 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
| US6086875A (en) | 1995-01-17 | 2000-07-11 | The Brigham And Women's Hospital, Inc. | Receptor specific transepithelial transport of immunogens |
| US6485726B1 (en) | 1995-01-17 | 2002-11-26 | The Brigham And Women's Hospital, Inc. | Receptor specific transepithelial transport of therapeutics |
| US6030613A (en) | 1995-01-17 | 2000-02-29 | The Brigham And Women's Hospital, Inc. | Receptor specific transepithelial transport of therapeutics |
| SE9503380D0 (sv) | 1995-09-29 | 1995-09-29 | Pharmacia Ab | Protein derivatives |
| US6458563B1 (en) | 1996-06-26 | 2002-10-01 | Emory University | Modified factor VIII |
| CA2225189C (en) | 1997-03-06 | 2010-05-25 | Queen's University At Kingston | Canine factor viii gene, protein and methods of use |
| GB9722131D0 (en) | 1997-10-20 | 1997-12-17 | Medical Res Council | Method |
| WO2001007072A1 (en) * | 1999-07-23 | 2001-02-01 | The Regents Of The University Of California | Modulation of platelet activation |
| EP1276856A4 (en) | 2000-04-12 | 2004-06-09 | Human Genome Sciences Inc | ALBUMIN FUSION PROTEINS |
| WO2001087922A2 (en) | 2000-05-16 | 2001-11-22 | Lipoxen Technologies Limited | Derivatisation of proteins in aqueous solution |
| US20030228309A1 (en) * | 2000-11-08 | 2003-12-11 | Theodora Salcedo | Antibodies that immunospecifically bind to TRAIL receptors |
| WO2002076489A1 (en) | 2001-03-09 | 2002-10-03 | Dyax Corp. | Serum albumin binding moieties |
| JP5424521B2 (ja) | 2001-12-21 | 2014-02-26 | ヒューマン ジノーム サイエンシーズ， インコーポレイテッド | アルブミン融合タンパク質 |
| US20080194481A1 (en) | 2001-12-21 | 2008-08-14 | Human Genome Sciences, Inc. | Albumin Fusion Proteins |
| KR101271635B1 (ko) | 2001-12-21 | 2013-06-12 | 휴먼 게놈 사이언시즈, 인코포레이티드 | 알부민 융합 단백질 |
| CA2479212A1 (en) | 2002-03-15 | 2003-09-25 | Brigham And Women's Hospital, Inc. | Central airway administration for systemic delivery of therapeutics |
| US7041635B2 (en) | 2003-01-28 | 2006-05-09 | In2Gen Co., Ltd. | Factor VIII polypeptide |
| CN1767857A (zh) | 2003-02-26 | 2006-05-03 | 尼克塔治疗亚拉巴马公司 | 聚合物－因子ⅷ部分共轭物 |
| WO2004076484A1 (en) * | 2003-02-27 | 2004-09-10 | National Research Council Of Canada | Peptide inhibitors of thrombin as potent anticoagulants |
| WO2005016949A2 (en) | 2003-08-12 | 2005-02-24 | Lipoxen Technologies Limited | Sialic acid derivatives |
| US7211559B2 (en) | 2003-10-31 | 2007-05-01 | University Of Maryland, Baltimore | Factor VIII compositions and methods |
| GB0516091D0 (en) * | 2005-08-04 | 2005-09-14 | Haemostatix Ltd | Therapeutic agent |
| MX2008001865A (es) | 2005-08-12 | 2008-04-15 | Human Genome Sciences Inc | Proteinas de fusion de albumina. |
| US7846445B2 (en) * | 2005-09-27 | 2010-12-07 | Amunix Operating, Inc. | Methods for production of unstructured recombinant polymers and uses thereof |
| MX2009002816A (es) | 2006-09-14 | 2009-05-28 | Human Genome Sciences Inc | Proteinas de fusion de albumina. |
| MX2009003470A (es) * | 2006-10-04 | 2009-04-14 | Novo Nordisk As | Azucares y glicopeptidos pegilados enlazados a glicerol. |
| AU2007338298B2 (en) * | 2006-12-22 | 2013-02-07 | Csl Behring Gmbh | Modified coagulation factors with prolonged in vivo half-life |
| ES2422007T3 (es) | 2007-06-21 | 2013-09-06 | Univ Muenchen Tech | Proteínas activas biológicas que tienen estabilidad aumentada in vivo y/o in vitro |
| GB2467700A (en) * | 2007-11-09 | 2010-08-11 | Baxter Int | Modified recombinant Factor VIII and von Willebrand Factor and methods of use |
| CA2728012C (en) * | 2008-06-24 | 2017-10-31 | Csl Behring Gmbh | Factor viii, von willebrand factor or complexes thereof with prolonged in vivo half-life |
| JP2012510060A (ja) * | 2008-11-24 | 2012-04-26 | バイエル・ヘルスケア・エルエルシー | シリカをベースとする活性化部分トロンボプラスチン時間アッセイにおけるｐｅｇ化血液凝固因子の活性の測定方法 |
| US8680050B2 (en) | 2009-02-03 | 2014-03-25 | Amunix Operating Inc. | Growth hormone polypeptides fused to extended recombinant polypeptides and methods of making and using same |
| US8703717B2 (en) | 2009-02-03 | 2014-04-22 | Amunix Operating Inc. | Growth hormone polypeptides and methods of making and using same |
| NZ606427A (en) | 2009-02-03 | 2014-10-31 | Amunix Operating Inc | Extended recombinant polypeptides and compositions comprising same |
| WO2010111414A1 (en) * | 2009-03-24 | 2010-09-30 | Bayer Healthcare Llc | Factor viii variants and methods of use |
| DK2440228T3 (en) | 2009-06-08 | 2018-12-17 | Amunix Operating Inc | Glucose regulating polypeptides and methods for their preparation and use |
| LT2440241T (lt) | 2009-06-08 | 2017-10-10 | Amunix Operating Inc. | Augimo hormonų polipeptidai ir jų gamybos bei panaudojimo būdai |
| EP2470670A4 (en) | 2009-08-24 | 2013-07-10 | Amunix Operating Inc | COAGULATION FACTOR VII COMPOSITIONS AND METHODS OF PREPARATION AND USE THEREOF |
| WO2011028344A2 (en) | 2009-08-25 | 2011-03-10 | Amunix Operating Inc. | Interleukin-1 receptor antagonist compositions and methods of making and using same |
| JP5544219B2 (ja) * | 2009-09-24 | 2014-07-09 | 富士フイルム株式会社 | 内視鏡システム |
| JP5876416B2 (ja) * | 2009-11-13 | 2016-03-02 | グリフオルス・セラピユーテイクス・インコーポレーテツドＧｒｉｆｏｌｓ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | フォンウィルブランド因子（ｖＷＦ）含有調製品並びにこれに関連する方法、キット及び使用 |
| WO2011069164A2 (en) * | 2009-12-06 | 2011-06-09 | Biogen Idec Ma Inc. | Factor viii-fc chimeric and hybrid polypeptides, and methods of use thereof |
| US20110312881A1 (en) * | 2009-12-21 | 2011-12-22 | Amunix, Inc. | Bifunctional polypeptide compositions and methods for treatment of metabolic and cardiovascular diseases |
| CA2804280A1 (en) | 2010-07-09 | 2012-01-12 | Biogen Idec Hemophilia Inc. | Chimeric clotting factors |
| US9611310B2 (en) | 2010-07-09 | 2017-04-04 | Bioverativ Therapeutics Inc. | Systems for factor VIII processing and methods thereof |
| US20130017997A1 (en) | 2010-08-19 | 2013-01-17 | Amunix Operating Inc. | Factor VIII Compositions and Methods of Making and Using Same |
| EP2804623B1 (en) * | 2012-01-12 | 2019-08-07 | Bioverativ Therapeutics Inc. | Chimeric factor viii polypeptides and uses thereof |
| BR112014019901A8 (pt) | 2012-02-15 | 2018-01-02 | Biogen Idec Inc | Proteínas de fator viii recombinante |
| ES2771208T3 (es) | 2012-02-15 | 2020-07-06 | Bioverativ Therapeutics Inc | Composiciones de factor VIII y métodos de preparación y uso de las mismas |
| EP2841451A1 (en) * | 2012-04-24 | 2015-03-04 | Novo Nordisk A/S | Compounds suitable for treatment of haemophilia |
| US10138291B2 (en) * | 2012-07-11 | 2018-11-27 | Bioverativ Therapeutics Inc. | Factor VIII complex with XTEN and von Willebrand Factor protein, and uses thereof |
| EP2796145B1 (en) * | 2013-04-22 | 2017-11-01 | CSL Ltd. | A covalent complex of von willebrand factor and faktor viii linked by a disulphide bridge |
| TW201536811A (zh) * | 2013-05-31 | 2015-10-01 | Biogen Idec Inc | 嵌合ｆｖｉｉ－ｘｔｅｎ分子及其用途 |
| US20160229903A1 (en) * | 2013-06-28 | 2016-08-11 | Biogen Ma Inc. | Thrombin cleavable linker |
| PT3091997T (pt) * | 2014-01-10 | 2022-09-29 | Bioverativ Therapeutics Inc | Proteínas quiméricas de fator viii e utilizações destas |
| DK3793588T3 (da) * | 2018-05-18 | 2025-06-16 | Bioverativ Therapeutics Inc | Fremgangsmåder til behandling af hæmofili a |
-
2014
- 2014-06-27 HK HK16111718.0A patent/HK1223302A1/zh unknown
- 2014-06-27 AU AU2014302100A patent/AU2014302100B2/en not_active Withdrawn - After Issue
- 2014-06-27 US US14/894,108 patent/US20160251408A1/en not_active Abandoned
- 2014-06-27 KR KR1020247032926A patent/KR102865153B1/ko active Active
- 2014-06-27 CA CA2913078A patent/CA2913078A1/en active Pending
- 2014-06-27 JP JP2016524268A patent/JP2016523919A/ja active Pending
- 2014-06-27 EP EP14817900.5A patent/EP3013358A4/en not_active Withdrawn
- 2014-06-27 CN CN201480029781.5A patent/CN105392495A/zh active Pending
- 2014-06-27 CN CN202110796045.4A patent/CN113817069A/zh active Pending
- 2014-06-27 EA EA201592022A patent/EA201592022A1/ru unknown
- 2014-06-27 KR KR1020227045978A patent/KR20230007555A/ko not_active Ceased
- 2014-06-27 KR KR1020157033268A patent/KR102666819B1/ko active Active
- 2014-06-27 SG SG11201509313PA patent/SG11201509313PA/en unknown
- 2014-06-27 NZ NZ713904A patent/NZ713904A/en unknown
- 2014-06-27 KR KR1020247004922A patent/KR102714760B1/ko active Active
- 2014-06-27 CN CN202110797628.9A patent/CN113831415A/zh active Pending
- 2014-06-27 MX MX2015016567A patent/MX2015016567A/es unknown
- 2014-06-27 SG SG10201710616XA patent/SG10201710616XA/en unknown
- 2014-06-27 EP EP24150415.8A patent/EP4368194A3/en active Pending
- 2014-06-27 SG SG10201913738YA patent/SG10201913738YA/en unknown
- 2014-06-27 WO PCT/US2014/044731 patent/WO2014210558A1/en not_active Ceased
- 2014-06-27 IL IL297611A patent/IL297611B2/en unknown
- 2014-06-30 TW TW109104938A patent/TWI770467B/zh active
- 2014-06-30 TW TW103122511A patent/TWI716340B/zh active
- 2014-06-30 TW TW111122793A patent/TWI844042B/zh active
-
2015
- 2015-11-04 IL IL242436A patent/IL242436B/en active IP Right Grant
- 2015-11-24 PH PH12015502614A patent/PH12015502614A1/en unknown
- 2015-12-23 CL CL2015003710A patent/CL2015003710A1/es unknown
-
2018
- 2018-10-17 JP JP2018195860A patent/JP2019010124A/ja active Pending
-
2019
- 2019-05-05 IL IL266462A patent/IL266462B2/en unknown
-
2020
- 2020-05-08 AU AU2020203063A patent/AU2020203063B2/en active Active
-
2021
- 2021-02-08 JP JP2021018123A patent/JP7005800B2/ja active Active
- 2021-09-20 US US17/479,705 patent/US20220106383A1/en not_active Abandoned
- 2021-10-05 JP JP2021163956A patent/JP7297837B2/ja active Active
-
2023
- 2023-06-14 JP JP2023097660A patent/JP7623426B2/ja active Active
- 2023-07-25 US US18/358,601 patent/US20240083975A1/en active Pending
- 2023-08-22 AU AU2023219840A patent/AU2023219840A1/en active Pending
-
2025
- 2025-01-15 JP JP2025005420A patent/JP2025061316A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016523919A5 (enExample) | ||
| JP2017503509A5 (enExample) | ||
| JP2015527882A5 (enExample) | ||
| JP2015504679A5 (enExample) | ||
| US11261437B2 (en) | Procoagulant compounds | |
| EP2417155B1 (en) | Targeted delivery of factor viii proteins to platelets | |
| JP6527918B2 (ja) | 第ｖｉｉｉ因子組成物、ならびに組成物の作製方法および用途 | |
| EP4461750A2 (en) | Novel interleukin-15 (il-15) fusion proteins and uses thereof | |
| EP2585098B1 (en) | Fzd8 extracellular domains and fzd8 extracellular domain fusion molecules for use in treating obesity and obesity-related disorders | |
| EP3144320B1 (en) | Fc fusion proteins comprising novel linkers or arrangements | |
| JP2019506166A5 (enExample) | ||
| JP2008504012A5 (enExample) | ||
| JP2013519699A5 (enExample) | ||
| RS58578B1 (sr) | Faktor viii himernih i hibridnih polipeptida i postupci za njihovu upotrebu | |
| JP2012520059A5 (enExample) | ||
| JP2011501951A5 (enExample) | ||
| JP7626514B2 (ja) | 改善された薬物動態を有する、グリコシル化ｖｗｆ融合タンパク質 | |
| KR20180029262A (ko) | 인자 ix 융합 단백질 및 이의 제조 방법 및 사용 방법 | |
| WO2009142773A4 (en) | Multivalent fibronectin based scaffold domain proteins | |
| TW201348254A (zh) | 重組因子ｖｉｉｉ蛋白 | |
| WO2011084711A2 (en) | Hair growth methods using fgfr3 extracellular domains | |
| JPWO2021243122A5 (enExample) | ||
| JP2020504081A5 (enExample) | ||
| KR20150083600A (ko) | 혈뇌장벽 투과성 펩티드 및 이를 포함하는 컨쥬게이트 | |
| CA3238005A1 (en) | Chimeric antigen receptors |